Key result
Nucleic acid-based therapies, particularly ASOs and siRNAs targeting liver cholesterol and lipoprotein metabolism, have shown promising results in early clinical trials for treating atherosclerosis.
Why the study?
RNA-based antisense oligonucleotides and small interfering RNAs are being developed for atherosclerosis risk factors, prompting a review of nucleic acid-based therapeutics and novel RNAs as potential future treatments.
Nucleic acid-based therapies, particularly ASOs and siRNAs targeting lipid metabolism, represent a promising emerging class of treatments for atherosclerosis.
Answers are grounded in this paper and cite their sources.
Promising early trial data support expanded research on ASO/siRNA lipid therapies; clinical use remains premature pending larger trials.
PURPOSE OF REVIEW: Atherosclerosis is characterized by accumulation of lipids and chronic inflammation in medium size to large arteries. Recently, RNA-based antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) are being developed, along with small molecule-based drugs and monoclonal antibodies, for the treatment of risk factors associated with atherosclerosis.. The purpose of this review is to describe nucleic acid-based therapeutics and introduce novel RNAs that might become future tools for treatment of atherosclerosis. RECENT FINDINGS: RNA-based inhibitors for PCSK9, Lp(a), ApoCIII, and ANGPTL3 have been successfully tested in phase II-III clinical trials. Moreover, multiple microRNA and long non-coding RNAs have been found to reduce atherogenesis in preclinical animal models. Clinical trials especially with ASOs and siRNAs directed to liver, targeting cholesterol and lipoprotein metabolism, have shown promising results. Additional research in larger patient cohorts is needed to fully evaluate the therapeutic potential of these new drugs.
No takes yet. Share an insight, caveat, or question.
Mäkinen et al. (2020) conducted a review in Atherosclerosis and Dyslipidemia. Nucleic Acid-Based Therapies (ASOs, siRNAs, miRNAs, lncRNAs) was evaluated. Nucleic acid-based therapies, particularly ASOs and siRNAs targeting liver cholesterol and lipoprotein metabolism, have shown promising results in early clinical trials for treating atherosclerosis.
Synapse has enriched 10 related papers. Consider them for comparative context: